Sgherza, N.; Battisti, O.; Curci, P.; Conticello, C.; Palmieri, S.; Derudas, D.; Germano, C.; Martino, E.A.; Mele, G.; Della Pepa, R.;
et al. Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595. Pharmaceuticals 2025, 18, 858.
https://doi.org/10.3390/ph18060858
AMA Style
Sgherza N, Battisti O, Curci P, Conticello C, Palmieri S, Derudas D, Germano C, Martino EA, Mele G, Della Pepa R,
et al. Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595. Pharmaceuticals. 2025; 18(6):858.
https://doi.org/10.3390/ph18060858
Chicago/Turabian Style
Sgherza, Nicola, Olga Battisti, Paola Curci, Concetta Conticello, Salvatore Palmieri, Daniele Derudas, Candida Germano, Enrica Antonia Martino, Giuseppe Mele, Roberta Della Pepa,
and et al. 2025. "Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595" Pharmaceuticals 18, no. 6: 858.
https://doi.org/10.3390/ph18060858
APA Style
Sgherza, N., Battisti, O., Curci, P., Conticello, C., Palmieri, S., Derudas, D., Germano, C., Martino, E. A., Mele, G., Della Pepa, R., Fazio, F., Mele, A., Rossini, B., Palazzo, G., Roccotelli, D., Rasola, S., Petrucci, M. T., Pastore, D., Tarantini, G.,
... Musto, P.
(2025). Correction: Sgherza et al. Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study. Pharmaceuticals 2025, 18, 595. Pharmaceuticals, 18(6), 858.
https://doi.org/10.3390/ph18060858
